BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 27
• 30
• 31

• Business

  Nuevolution Appoints Ton Berkien As Chief Business Officer

  December 9, 2013

   · 

  4 min read
• Drug Development

  Nimbus Discovery IRAK4 Inhibitor Demonstrates Synergistic Effects In Preclinical Studies With Three Kinase Inhibitors For The Treatment Of Lymphoid Malignancies

  December 9, 2013

   · 

  1 min read
• Drug Development

  Biogen Idec, Inc. (Massachusetts) And Swedish Orphan Biovitrum Release: New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ And ELOCTATE™ Across Multiple Hemophilia Populations

  December 9, 2013

   · 

  1 min read
• BioCapital

  MaxCyte, Inc. Presents Data On Stable Cell Line Generation And Rapid, High Titer Production Of Antibodies And Proteins Using Flow Electroporation

  December 9, 2013

   · 

  1 min read
• Drug Development

  NOXXON Pharma AG Release: Interim Phase 2a Results For Spiegelmer® Olaptesed Pegol (NOX-A12) In CLL And MM Studies

  December 9, 2013

   · 

  1 min read
• Business

  Charles River Laboratories (Massachusetts) Announces Organizational Changes To Enhance Global Capabilities

  December 9, 2013

   · 

  1 min read
• Drug Development

  Sunovion Pharmaceuticals Inc. Presents Positive Results From Two Phase 3 Studies Of Once-Daily Aptiom® (Eslicarbazepine Acetate) As Monotherapy Treatment For Partial-Onset Seizures

  December 9, 2013

   · 

  1 min read
• Drug Development

  Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (TRU-016) In Combination With Bendamustine In People With Relapsed Chronic Lymphocytic Leukemia

  December 9, 2013

   · 

  1 min read
• Infinity Pharmaceuticals Inc. Reports Updated Phase 1 Data Of IPI-145 In Indolent Non-Hodgkin Lymphoma At American Society of Hematology Annual Meeting

  December 9, 2013

   · 

  1 min read
• First Analysis Of Extended Dosing With Celgene International Sárl Epigenetic Agent CC-486 In Patients With Higher-Risk Myelodysplastic Syndromes Presented At American Society of Hematology

  December 9, 2013

   · 

  1 min read